

*The Stock Exchange of Hong Kong Limited (the “Stock Exchange”) takes no responsibility for the contents of this announcement, makes no representation as to its accuracy or completeness and expressly disclaims any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

*This announcement, for which the directors (the “Directors”) of Everpride Biopharmaceutical Company Limited (the “Company”) collectively and individually accept full responsibility, includes particulars given in compliance with the Rules Governing the Listing of Securities on the Growth Enterprise Market of the Stock Exchange for the purpose of giving information with regard to the Company. The Directors, having made all reasonable enquiries, confirm that, to the best of their knowledge and belief: (i) the information contained in this announcement is accurate and complete in all material respects and not misleading; (ii) there are no other matters the omission of which would make any statement in this announcement misleading; and (iii) all opinions expressed in this announcement have been arrived at after due and careful consideration and are founded on bases and assumptions that are fair and reasonable.*



## **EVERPRIDE BIOPHARMACEUTICAL COMPANY LIMITED**

**中遠威生物製藥有限公司\***

*(Incorporated in the Cayman Islands with limited liability)*

**(Stock Code: 8019)**

### **PROFIT WARNING**

This announcement is made by the Company pursuant to Rule 17.10 of the GEM Listing Rules.

The Board wishes to inform the shareholders of the Company and potential investors that the Group is expected to record a substantial loss for the year ended 31 December 2008 based on assessment of current unaudited financial information available.

**Shareholders of the Company and potential investors are advised to exercise caution when dealing in the shares of the Company.**

The board of the directors (the “Board”) of Everpride Biopharmaceutical Company Limited (the “Company”) wishes to inform the shareholders of the Company and potential investors that the Group is expected to record a substantial loss for the year ended 31 December 2008 based on assessment of current unaudited financial information available. The expected loss is mainly attributable to substantial increase of advertising and promotion expenses and research and development costs. The Board will continue to review the Group’s operations and strategies to meet the challenges ahead.

The Company is still in process of finalizing the Group’s annual results for the year ended 31 December 2008. Information contained in this announcement is based on unaudited financial information which is subject to audit by the Company’s independent auditor. Shareholders of the Company and potential investors are advised to read carefully the Group’s annual results announcement for the year ended 31 December 2008

which is expected to be published in March 2009.

**Shareholders of the Company and potential investors are therefore advised to exercise caution when dealing in the shares of the Company.**

By Order of the Board  
**EVERPRIDE BIOPHARMACEUTICAL COMPANY LIMITED**  
**Leung King Fai**  
*Company Secretary*

Hong Kong, 19 March 2009

*As at the date of this announcement, Mr. Chung Chi Mang, Mr. Zhong Zhi Gang, Mr. Xie Xiaodong and Mr. Mu Yong are the executive directors of the Company and Mr. Chau On Ta Yuen, Mr. Ho Leong Leong, Lawrence and Mr. Ng Kay Kwok are the independent non-executive directors of the Company.*

*This announcement will remain on the GEM website with the domain name of [www.hkgem.com](http://www.hkgem.com) on the "Latest Company Announcements" page for at least seven days from the date of its posting.*

\* For identification purposes only